CL2022002239A1 - Tafoxiparina para el tratamiento de la preeclampsia - Google Patents

Tafoxiparina para el tratamiento de la preeclampsia

Info

Publication number
CL2022002239A1
CL2022002239A1 CL2022002239A CL2022002239A CL2022002239A1 CL 2022002239 A1 CL2022002239 A1 CL 2022002239A1 CL 2022002239 A CL2022002239 A CL 2022002239A CL 2022002239 A CL2022002239 A CL 2022002239A CL 2022002239 A1 CL2022002239 A1 CL 2022002239A1
Authority
CL
Chile
Prior art keywords
tafoxiparin
treatment
eclampsia
preeclampsia
combination
Prior art date
Application number
CL2022002239A
Other languages
English (en)
Inventor
Degling-Wikingsson Lena
Ekman-Ordeberg Gunvor
Hansson Stefan
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of CL2022002239A1 publication Critical patent/CL2022002239A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se relaciona con el uso de la tafoxiparina derivada de heparina en el tratamiento de la preeclampsia (PE). El tratamiento puede ser monoterapia o terapia de combinación, donde la tafoxiparina se utiliza en combinación con un agente (fármaco) utilizado como terapia para cuidado estándar de la preeclampsia (PE).
CL2022002239A 2020-02-17 2022-08-17 Tafoxiparina para el tratamiento de la preeclampsia CL2022002239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2000033 2020-02-17

Publications (1)

Publication Number Publication Date
CL2022002239A1 true CL2022002239A1 (es) 2023-04-10

Family

ID=74668828

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002239A CL2022002239A1 (es) 2020-02-17 2022-08-17 Tafoxiparina para el tratamiento de la preeclampsia

Country Status (13)

Country Link
US (1) US20230144378A1 (es)
EP (1) EP4106765A1 (es)
JP (1) JP2023512920A (es)
KR (1) KR20220142508A (es)
CN (1) CN115103679A (es)
AU (1) AU2021223494A1 (es)
BR (1) BR112022014456A2 (es)
CA (1) CA3169421A1 (es)
CL (1) CL2022002239A1 (es)
CO (1) CO2022013055A2 (es)
IL (1) IL295184A (es)
MX (1) MX2022010093A (es)
WO (1) WO2021165240A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355658A1 (en) 2022-05-03 2023-11-09 Dilafor Ab Medical use of tafoxiparin
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
MX351104B (es) 2011-12-19 2017-10-02 Dilafor Ab Nuevos glucosaminoglucanos con baja actividad anticoagulante.
EP2830635A4 (en) 2012-03-26 2016-03-16 Dilafor Ab COMBINATION TREATMENT OF ILLUSTRATED SULFATED GLYCOSAMINOGLYCANES
AU2013240598A1 (en) 2012-03-26 2014-10-02 Dilafor Ab Method for treatment of labor arrest
AU2013260209A1 (en) 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes

Also Published As

Publication number Publication date
MX2022010093A (es) 2022-09-02
WO2021165240A1 (en) 2021-08-26
JP2023512920A (ja) 2023-03-30
IL295184A (en) 2022-09-01
BR112022014456A2 (pt) 2022-09-13
KR20220142508A (ko) 2022-10-21
EP4106765A1 (en) 2022-12-28
CO2022013055A2 (es) 2022-09-30
CA3169421A1 (en) 2021-08-26
CN115103679A (zh) 2022-09-23
AU2021223494A1 (en) 2022-08-04
US20230144378A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
ECSP22061711A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
CO2022000481A2 (es) Inhibidores de enzimas
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
UY37832A (es) Dihidrooxadiazinonas
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
CO2022003156A2 (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112021018858A2 (pt) Chiauranibe para tratamento de câncer de pulmão de células pequenas
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.